Efficacy and Safety of Esketamine in the Treatment of Patients With Treatment Resistant Major Depression

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-005992-17

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of the study is to evaluate the efficacy, safety, and tolerability of esketamine in subjects with treatment resistant depression. Efficacy in improving symptoms compared with a placebo will be assessed by the changes from randomisation to end of week 1 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.


Critère d'inclusion

  • Treatment-resistant Major Depression